Ascendis Pharma bags YORVIPATH FDA approval for adult hypoparathyroidism

In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted approval to Ascendis Pharma A/S’s YORVIPATH (palopegteriparatide), making it the first and ... Read More